ArticleCureus2025
The Role of Breast Examination in Prenatal Care: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy-associated breast cancer (PABC) is a relatively rare but clinically significant condition. Diagnosis is often delayed, as physiological breast changes during pregnancy can obscure malignant findings, resulting in more advanced disease at presentation. PABC poses unique diagnostic and therapeutic challenges due to its rarity and the complexity of managing maternal and fetal health. This case highlights these challenges in a 35-year-old woman at 30 weeks of gestation who presented with a large, painful left breast mass. Open biopsy confirmed grade 3, triple-negative, infiltrating ductal carcinoma. Axillary lymphadenopathy was present, and staging revealed liver, bone, and lung metastases. Neoadjuvant chemotherapy was administered, followed two weeks after the last dose by cesarean delivery at 37+5 weeks, resulting in the birth of a healthy infant without complications. Despite the initial response to treatment, the disease progressed three months later. Molecular therapy was subsequently administered, but the patient ultimately succumbed 16 months after the initial diagnosis. Current guidelines do not recommend routine breast examinations during antenatal care; however, this case underscores the importance of breast evaluation during pregnancy as both a medical and psychological imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.